Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

3.365 -0.005 (-0.15%)
Streaming Delayed Price Updated: 10:56 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maravai LifeSciences Holdings, Inc. - Class A common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What to Expect from Maravai LifeSciences's Earnings
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Insights Ahead: Maravai LifeSciences's Quarterly Earnings
 
Via Benzinga
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Earnings Scheduled For August 11, 2025
 
Via Benzinga
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
From Kahn Swick & Foti, LLC
Via Business Wire
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
From Kahn Swick & Foti, LLC
Via Business Wire
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
From TriLink BioTechnologies
Via Business Wire
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciencesReleases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
From TriLink BioTechnologies
Via Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
From TriLink BioTechnologies
Via Business Wire
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
 
Via Benzinga
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts
 
Via Benzinga
Maravai Lifesciences Reports First Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
From Pomerantz LLP
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
From Faruqi & Faruqi, LLP
Via Business Wire
MRVI Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
MRVI Deadline in 4 Days: Kessler Topaz Meltzer &amp; Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - May 1, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai... 
Via TheNewswire.com
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.